



2nd International Electronic Conference on Medicinal Chemistry

1-30 November 2016

chaired by Dr. Jean Jacques Vanden Eynde

sponsored by



pharmaceuticals

Synthesis of bioactive 2-(arylamino)thiazolo[5,4-f]quinazolin-9-ones via Hügershoff reaction or Cu catalyzed intramolecular C-S bond formation

Damien Hédou ¹, Carole Dubouilh ¹, Nadège Loaëc ^{2,3}, Laurent Meijer ³,
Corinne Fruit ¹ and Thierry Besson ^{1,*}

¹ Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France;



² Protein Phosphorylation & Human Disease group, Station Biologique, 29680 Roscoff, France

³ Manros Therapeutics, Centre de Perharidy, 29680 Roscoff, France



* Corresponding author: thierry.besson@univ-Rouen.fr

Synthesis of bioactive 2-(arylamino)thiazolo[5,4-f]quinazolin-9-ones via Hügershoff reaction or Cu catalyzed intramolecular C-S bond formation.



Abstract: A library of thirty eight novel thiazolo[5,4-*f*]quinazolin-9(8*H*)-one derivatives (series **8**, **10**, **14** and **17**) was prepared via the Hügershoff reaction and a Cu catalyzed intramolecular C-S bond formation, helped by microwave-assisted technology when required. The efficient multistep synthesis of the key 6-amino-3-cyclopropylquinazolin-4(3*H*)-one (**3**) has been reinvestigated and performed on a multi-gram scale from the starting 5-nitroanthranilic acid. The inhibitory potency of the final products was evaluated against five kinases involved in Alzheimer's disease and showed that some molecules of the **17** series described in this paper are particularly promising for the development of novel multi-target inhibitors of kinases.

Keywords: Hügershoff reaction; thiazolo[5,4-*f*]quinazolin-9(8*H*)-ones; microwave-assisted synthesis; protein kinases



Introduction

Our research group is mainly invested in the synthesis of C,N,S-containing bioactive molecules able to modulate the activity of deregulated kinases (CDK5, GSK-3, CLK1, CK1 and the dual-specificity kinase DYRK1A) involved to some extent in Alzheimer's disease (AD). Among them some thiazolo[5,4-*f*]quinazolin-9(8*H*)-ones (Figure 1) have been revealed of particular interest in the design of multi-target-directed ligands (MTDLs), a new strategy for the development of new tools against neurodegenerative diseases.

The target molecules were thiazolo[5,4-*f*]quinazolin-9-ones substituted in position N-8 by a cyclopropyl chain (Figure 1).





Figure 1. General formula of lead kinases inhibitors previously described [1-5] and new molecules targeted.



Results and discussion : Envisioned retrosynthetic pathway and the key 6-amino-3-cyclopropylquinazolin-4(3H)-one (**3**).

The first planned strategy uses the Hügershoff reaction, a bromine-mediated cyclization process involving electrophilic addition. The second route imagined concerns a metal catalyzed intramolecular C-S bond formation on the synthesis of variously 2-substituted benzothiazoles from thiobenzanilides (Scheme 1).




Scheme 1. Envisioned retrosynthetic pathway for the synthesis of the target products, *via* Hügershoff reaction or transition metal-catalyzed intramolecular C-S bond formation.



Results and discussion: Synthesis of the key 6-amino-3-cyclopropylquinazolin-4(3H)-one (**3**).

The key 6-amino-3-cyclopropylquinazolin-4(3H)-one (**3**) was obtained via an efficient microwave-assisted MCR procedure.




Scheme 2. Sequential MCR procedure for convenient synthesis of 6-amino-3-cyclopropylquinazolin-4(3H)-one (**3**) from **1**. *Reagents and conditions:* (a) Step 1: DMFDMA (2.5 equiv), DMF, 100 °C (μ w), 15 min; Step 2: Cyclopropylamine (1.1 eq), AcOH, 100 °C (μ w), 15 min; 85%; (b) HCO₂NH₄ (5.0 equiv), Pd/C (10%), EtOH, 85 °C (μ w), 15 min; 85%.




Results and discussion : Synthesis of 2-aminoarylthiazolo[5,4-f]quinazolin-9-ones via Hügershoff reaction

Synthetic routes for access to the key isothiocyanate **4**.


Route 1 : with thiophosgene



Appel salt



Pyr. (2 equiv)
DCM, r.t., 3 h



Route 2 : via Appel salt chemistry


DBU
(4.0 equiv)

DCM,
-78 °C then
r.t., 3 h

DBU (1 equiv)
DCM, r.t., 1 h

DBU (3.0 equiv)

DCM,
-78 °C then r.t., 2 h



Results and discussion : Synthesis of thiourea **7a-l** from amine **3** or from isothiocyanate **4**.





Table 1. Chemical structures and yields obtained for the synthesis of series **7a-l**.

-R ^a	Compound	Method	Time (h)	Yield ^b (%)
Ph	7a	A/B	1/2	84/80
4-Cl-C ₆ H ₄	7b	A	1	91
4-F-C ₆ H ₄	7c	B	2	90
4-CF ₃ -C ₆ H ₄	7d	B ^c	1	84
4-NO ₂ -C ₆ H ₄	7e	A	0.5	74
2,4-diCl-C ₆ H ₃	7f	B	1	89
3-Py	7g	B ^c	2	89
4-Me-C ₆ H ₄	7h	A	2	89
4-OMe-C ₆ H ₄	7i	A	2	87
4-NMe ₂ -C ₆ H ₄	7j	B	10 min	87




Results and discussion : Synthesis of 2-aminoarylthiazolo[5,4-f]quinazolin-9-ones via Hügershoff reaction.



The cyclization was not regioselective. The phenyl group (A) of the starting diaryl thiourea **7a** possessed the most electron-rich *ortho*-carbon, compared to the quinazolin-4-one ring B. Compounds **10** are the major products.





Results and discussion : Synthesis of 2-aminoarylthiazolo[5,4-f]quinazolin-9-ones via Hügershoff reaction.




7b-g

R = 4-Cl, 4-F, 4-CF₃, 4-NO₂, 2,4-diCl
X = CH or N (R = H)



8b-g (45-90%)



9b-e (traces, not purified)

Table 2. Chemical structures and yields obtained for the synthesis of series **8a-g** via the Hügershoff reaction.

	Compound	Time (h)	Yield ^a (%)
	8a	0.5	10 ^{b,c}
	8b	1	- ^d
	8c	1	45 ^b
	8d	1	79 ^b
	8e	4	86 ^b
	8f	1.5	90
	8g	4	80


^a Isolated yield. ^b Traces of compounds of the 9 series were detected but not purified

Electron-deficient phenyl substituents are present in A cycle of the thiourea derivatives.



Results and discussion : Synthesis of 2-aminoaryl- and 2-aminoalkylthiazolo[5,4-f]quinazolin-9-ones via Metal Catalyzed C-S Bond Formation.

Synthesis of thiourea **12** via condensation of aniline with isothiocyanate **13**.




Formation of the isothiocyanate function was performed before bromination of the skeleton



Results and discussion : Synthesis of 2-aminoaryl- and 2-aminoalkylthiazolo[5,4-f]quinazolin-9-ones via Metal Catalyzed C-S Bond Formation


A sequential one-pot version of the transformation of isothiocyanate **13** into the tricyclic arene **8** series was considered.

This approach required the complete conversion of the starting material **13** into the corresponding thiourea intermediate (in square brackets) before addition of other reagents (CuI and Cs₂CO₃) and microwave-assisted cyclization by heating for 1 h.



Results and discussion : Synthesis of 2-aminoaryl- and 2-aminoalkylthiazolo[5,4-f]quinazolin-9-ones via Metal Catalyzed C-S Bond Formation.

Depending on the nature of aniline, the conversion time can vary from 30 min (electron-rich compounds *e.g.* 4-OMe, 3,4-diOMe or 4-NMe₂ anilines) to an overnight stirring (12 h).



Because electron-poor anilines required several hours for completion of the first part of the reaction, the Hügershoff reaction was found to be more efficient in these cases (products **8d–f**).


-R ¹	-R ²	Compound	Time ^a (h)	Yield ^b (%)
	H	8a	1	80
	H	8c	2	96
	H	8h	1	89
	H	8i	0.5	88
	H	8j	0.5	87
	H	8k	0.5	86
	H	8l	0.5	90
	H	8m	12	77

^a Time of the conversion of 13 into the corresponding thioureas (step 1); ^b Isolated yield.



Results and discussion : Synthesis of 2-aminoaryl- and 2-aminoalkylthiazolo[5,4-f]quinazolin-9-ones via Metal Catalyzed C-S Bond Formation.

Microwave-assisted heating at 80 °C for 1 h complete the sequence to afford the expected cyclized compounds (series **14a–f**) in very good yields (80%–96%, see Table 5).




-R ¹	-R ²	Compound	Time ^a (h)	Yield ^b (%)
	H	14a	0.5	80
	H	14b	0.5	96
	H	14c	0.5	89
	H	14d	0.5	88
	H	14e	0.5	87
	H	14f	0.5	86

^a Time of the conversion of 13 into the corresponding thioureas (step 1); ^b Isolated yield.



Results and discussion : Synthesis of carboximidamides **17a-f** from brominated amine **11**.



$-\text{R}^1$	$-\text{R}^2$	Compound	Time ^a (min)	Yield ^b (%)
	H	17a	45	82
	H	17b	45	99
	H	17c	45	87
	H	17d	45	57
	H	17e	90	60
	H	17f	180	54

^a Time of the conversion of **16** into the corresponding carboximidamides; ^b Isolated yield.

- Regio-selective intramolecular C-S coupling-reaction, catalyzed by CuI.

- A one-pot sequential process helped by microwave-assisted heating. It allowed the convenient synthesis of new thiazoloquinazolin-9-ones.



Results and discussion : Kinase inhibitory activity^{a,b,c} of the thiazolo[5,4-f]quinazoline series (7a-l, 8a-m, 10a and 10l, 14a-f and 17a-f).

Compounds	CDK5/p25	CK1d/e	CLK1	DYRK1A	GSK-3a/b
7a-l	>10	>10	>10	>10	≥10
8a	>10	>10	3.4	>10	≥10
8c-f	>10	>10	>10	>10	≥10
8g	>10	>10	1.7	>10	≥10
8h-i	>10	>10	>10	>10	≥10
8j	>10	>10	1.3	2.0	7.3
8k-m	>10	>10	>10	>10	≥10
10a	>10	>10	5.2	4.8	≥10
10l	>10	>10	>10	>10	≥10
14a	>10	>10	3.4	>10	>10
14b	>10	>10	>10	>10	≥10
14c	>10	>10	>10	>10	≥10
14d	>10	>10	8.1	8.2	≥10
14e	>10	>10	5.3	>10	≥10
14f	>10	>10	>10	>10	≥10
17a	>10	>10	1.0	0.67	0.4
17b	>10	>10	0.29	4.4	1.1
17c	>10	>10	2.3	3.2	2.8
17d	>10	>10	2.1	2.9	3.9
17e	>10	1.9	0.38	0.14	0.23
17f	>10	>10	0.61	0.82	0.49
Harmine	>10	1.5	0.026	0.029	>10


All compounds were first tested at a final concentration of 10 μM. Compounds showing less than 50% inhibition were considered as inactive (IC₅₀ >10 μM). Compounds displaying more than 50% inhibition at 10 μM were next tested over a wide range of concentrations (usually 0.01 to 10 μM), and IC₅₀ values were determined from the dose-response curves (Sigma-Plot). *Harmine* is a β-carboline alkaloid known to be a potent inhibitor of DYRK1A. It was also tested as positive control and its IC₅₀ values were compared to those obtained for the compounds under study.

The two most active molecules

^a IC₅₀ values are reported in μM. The most significant results are presented in bold; ^b Kinases activities were assayed in triplicate. Typically, the standard deviation of single data points was below 10%.




Results and discussion : The two most active molecules : **17e** and **17f**




7, 8, 10 and 14 series

Inactive compounds on
CDK5, CK1, CLK1, DYRK1A, GSK3



17e

CLK1 IC₅₀ (μM) : 0.38
DYRK1A IC₅₀ (μM) : 0.14
GSK3α/β IC₅₀ (μM) : 0.23



17f

CLK1 IC₅₀ (μM) : 0.61
DYRK1A IC₅₀ (μM) : 0.82
GSK3α/β IC₅₀ (μM) : 0.49

Comparing the results of 2-aminosubstituted derivatives and their carboximidamides analogs, it seems rather obvious that having such molecular scaffolds with submicromolar affinities for various kinases is related to the presence of **carboximidamide or carboximidate functions** that result from the substitution of a carbonitrile group itself present in position 2 of the thiazole.



Conclusion

- A library of 38 novel 8-aminoaryl thiazolo[5,4-*f*]quinazolin-9(8*H*)-ones (**8**, **10**, **14** and **17** series) has been prepared, using microwave-assisted technology:
- An efficient multistep synthesis of the key 6-amino-3-cyclopropylquinazolin-4(3*H*)-one (**3**) was developed and optimized to the multigram scale.
- The Hügershoff reaction was re-investigated under microwaves.
- A CuI catalyzed ligand-free intramolecular C-S bond formation was also developed.
- Molecules of the **8**, **10** and **14** series described in this paper are not pertinent for the development of kinases inhibitors.
- The most active compounds are carboximidamides analogues (**17** series) of the target compounds that shown submicromolar IC₅₀ values for CLK1, DYRK1A and GSK-3 α/β over the other tested enzymes.



References :

For more complete information see :

1. Logé, C.; Testard, A.; Thiéry, V.; Lozach, O.; Blairvacq, M.; Robert, J.-M.; Meijer, L.; Besson, T. Novel 9-oxo-thiazolo[5,4-*f*]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies. *Eur. J. Med. Chem.* **2008**, *43*, 1469–1477, doi:10.1016/j.ejmech.2007.09.020.
2. Testard, A.; Logé, C.; Léger, B.; Robert, J.-M.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiéry, V.; Besson, T. Thiazolo[5,4-*f*]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3419–3423, doi:10.1016/j.bmcl.2006.04.006.
3. Foucourt, A.; Hédou, D.; Dubouilh-Benard, C.; Désiré, L.; Casagrande, A.-S.; Leblond, B.; Loaëc, N.; Meijer, L.; Besson, T. Design and synthesis of thiazolo[5,4-*f*]quinazolines as DYRK1A inhibitors, Part I. *Molecules* **2014**, *19*, 15546–15571, doi:10.3390/molecules191015546.
4. Foucourt, A.; Hédou, D.; Dubouilh-Benard, C.; Désiré, L.; Casagrande, A.-S.; Leblond, B.; Loaëc, N.; Meijer, L.; Besson, T. Design and synthesis of thiazolo[5,4-*f*]quinazolines as DYRK1A inhibitors, Part II. *Molecules* **2014**, *19*, 15411–15439, doi:10.3390/molecules191015411.
5. Hédou, D.; Godeau, J.; Loaëc, N.; Meijer, L.; Fruit, C.; Besson, T. Synthesis of Thiazolo[5,4-*f*]quinazolin-9(8*H*)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases. *Molecules* **2016**, *21*, 578, doi:10.3390/molecules21050578.



Acknowledgments

Financial support from the MESR (French Ministère de l'Enseignement Supérieur & de la Recherche) is gratefully acknowledged for the doctoral fellowships to D.H.. We thank the LABEX SynOrg (ANR-11-LABX-0029) for financial support. We also acknowledge Milestone S.r.l. (Italy) for provision of multi-mode microwave reactor (Start STM) and for technical support. This research was partly supported by grants from the 'Fonds Unique Interministériel' (FUI) TRIAD (LM) projects, the "Fondation Jérôme Lejeune" (LM), and an FP7-KBBE-2012 grant (BlueGenics) to LM.

